Role of splenectomy in the treatment of myelofibrosis


Cite item

Full Text

Abstract

AIM: To evaluate the clinical and hematologic efficiency of splenectomy (SE) in patients with myelofibrosis (MF) resistant to conventional traditional treatment/MATERIAL AND METHODS: Case histories were retrospectively analyzed in 52 MF patients who had been followed up at the Hematology Research Center, Ministry of Health of the Russian Federation, in 2004 to 2012 and undergone therapeutic SE (47 patients with primary myelofibrosis, 4 with postpolycythemia myelofibrosis, and 1 with postthrombocythemia myelofibrosis). The mean age was 47 years at diagnosis and 53 years before surgery. The patients younger than 50 years of age constituted 60%. Massive and giant splenomegaly was detected in 37 (71%) patients. The spleen weighing 0.9 to 2.9 and 3 to 7 kg was removed in 15 (29%) and 35 (67%) patients, respectively. In 2 cases, the weight of the removed spleen was as much as 10 and 11 kg/RESULTS: By the moment of SE, the disease duration averaged 76 (from 1 to 240) months. Twenty-one (40%) patients developed perioperative complications, including bleeding (15%), thrombosis (11.5%), and infectious complications (13.5%). There were no deaths from surgical interventions in the intra- and early postoperative periods. In more than 80% of the patients after SE, their general condition improved and the symptoms of intoxication disappeared; in the majority of patients, the therapeutic effect lasted about 2 years. In the follow-up period, 33 (63%) patients died; the time to death averaged 27 (1-84) months following SE. The causes of death were blast transformation in 27 (82%) patients and comorbidity in 6 (18%); 19 (37%) patients with an average post-SE follow-up of 37 (4-72) months continued hydroxyurea treatment. The median survival after SE was equal to 3 years; the median overall survival was 11 years/CONCLUSION: SE is effective palliative care with an acceptable level of occurring complications for individual patients with MF. Contraindications to SE as blast crisis and severe comorbidities should be strictly taken into account.

Full Text

Роль спленэктомии при лечении больных миелофиброзом. - Резюме. Цель исследования. Оценить клинико-гематологическую эффективность спленэктомии (СЭ) у больных миелофиброзом (МФ), резистентным к традиционным методам лечения. Материалы и методы. Ретроспективно проанализировали истории болезни 52 больных МФ, которые наблюдались в Гематологическом научном центре (ГНЦ) Минздрава РФ с 2004 по 2012 г. и подвергались лечебной СЭ: 47 пациентов первичным миелофиброзом, 4 - постполицитемическим миелофиброзом и 1 - посттромбоцитемическим миелофибро­зом. Средний возраст при установлении диагноза составил 47 лет, а перед операцией - 53 года. Пациенты моложе 50 лет составили 60%. Массивная и гигантская спленомегалия была выявлена у 37 (71%) больных. У 15 (29%) больных удалена селезенка массой от 0,9 до 2,9 кг, у 35 (67%) - от 3 до 7 кг. В 2 случаях масса удаленной селезенки достигала 10 и 11 кг. Результаты. К моменту СЭ длительность заболевания составляла в среднем 76 (от 1 до 240) мес. Периоперационные осложнения встречались у 21 (40%) пациента, включая кровотечения (15%), тромбозы (11,5%), инфекционные ослож­нения (13,5%). Летальных исходов в интра- и раннем послеоперационном периодах не зафиксировано. У более чем 80% пациентов после СЭ исчезли симптомы интоксикации и улучшилось общее состояние, лечебный эффект у большинства больных длился около 2 лет. За период наблюдения умерли 33 (63%) пациента, период до смерти в среднем составил 27 (1-84) мес после СЭ. От бласттрансформации заболевания умерли 27 (82%) больных, от сопутствующей патологии - 6 (18%); 19 (37%) больных со средним сроком наблюдения после СЭ 37 (4-72) мес продолжают лечение гидроксимочевиной. Медиана продолжительности жизни после СЭ равна 3 годам, медиана общей продолжительности жизни - 11 годам. Заключение. СЭ является эффективным паллиативным методом лечения с допустимым уровнем возникающих осложнений для отдельных пациентов с МФ. Противопоказания к СЭ в виде бластного криза и тяжелых сопутствующих заболеваний должны строго учитываться.
×

References

  1. Barosi G. Myeiofibrosis with myeloid metaplasis diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954 -2970.
  2. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520-8530.
  3. Mesa R.A., Verstjvsek S., Cervantes F. et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post PV MF), post essential thrombocythemia myelofibrosis (post ET MF), blast phas PMF (PMF BP): consensus on terminology by the international Working Group tor Myelofibrosis Research and Tratment (IWG-MRT). Leuk Res 2007; 31: 737-740.
  4. Barosi G., Mesa R.A., Thiele J. et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
  5. Tefferi A., Thiele J., Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
  6. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
  7. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
  8. Cervantes F., Dupriez B., Pereira A. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
  9. Kralowics R., Passamonti F., Buder A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
  10. Levine R.L., Wadleigh M., Cool J. et al. Activation mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
  11. Pikman Y., Lee B.H., Mercher T. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PloS Med 2006; 3: 1140-1151.
  12. Pardanani A., Lasho T.L., Finke C. et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
  13. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
  14. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86 (12): 1017-1026.
  15. Patnaik M.M., Caramazza D., Gangat N. et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010; 84: 105-108.
  16. Passamonti F., Cervantes F., Vannucchi A.M. et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116: 2857-2858.
  17. Elena C., Passamonti F., Rumi E. et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011; 96: 167-170.
  18. Gangat N., Caramazza D., Vaidya R. et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
  19. Cervantes F. How I treat splenomegaly in myelofibrosis. Blood Cancer J 2011; 1 (10): e37.
  20. Cervantes F., Mesa R., Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377-383.
  21. Martinez-Trillos A., Gaya A., Maffioli M. et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010; 89: 1233-1237.
  22. Thomas D.A., Giles F.J., Albitar M. et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106: 1974-1984.
  23. Quintas-Cardama A., Kantarjian H.M., Manshouri T. et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760-4766.
  24. Kroger N., Holler E., Kobbe G. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
  25. Ballen K.K., Shrestha S., Sobocinski K.A. et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
  26. Deeg H.J., Appelbaum F.R. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood 2011; 117: 7185.
  27. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
  28. Huang J., Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83: 154-155.
  29. Tefferi A., Verstovsek S., Barosi G. et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
  30. Mishchenko E., Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010; 85: 192-199.
  31. Tefferi A., Mesa R.A., Nagorney D.M. et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
  32. Cervantes F., Mesa R., Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377-383.
  33. Mesa R.A., Nagorney D.S., Schwager S. et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
  34. Barosi G., Ambrosetti A., Centra A. et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630.
  35. Ковалева Л.Г., Карагюлян С.Р., Колосова Л.Ю. и др. Спленэктомия при сублейкемическом миелозе. Гематол и трансфузиол 2004; 5: 14-21.
  36. Карагюлян С.Р., Гржимоловский А.В., Данишьян К.И. Хирургические доступы к селезенке. Анналы хир гепатол 2006; 2: 92-99.
  37. Силаев М.А. Спленэктомия при массивной и гигантской спленомегалии у гематологических больных: Автореф. дис. … канд мед наук. М 2012: 15-17.
  38. Галузяк B.C., Карагюлян С.Р., Рыжко В.В. и др. Спленэктомия при зрелоклеточной лимфоме селезенки у больных старшего возраста. Клин герантол 2004; 5: 20-27.
  39. Галузяк В.С., Карагюлян С.Р., Рыжко В.В. и др. Спленэктомия при сублейкемическом миелозе. Гематол и трансфузиол 2004; 5: 14-21.
  40. Любимова Л.С., Савченко В.Г., Менделеева Л.П. и др. Трансплантация аллогенного костного мозга при хроническом миелолейкозе. Тер арх 2004; 7: 18-24.
  41. Покровская О.С., Менделеева Л.П., Капланская И.Б. и др. Ангиогенез в костном мозге больных множественной миеломой на различных этапах высокодозной химиотерапии. Клин онкогематол 2010; 4: 347-353.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies